Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its in-house developed antibody-drug conjugate (ADC), SHR-A2009, has received fast-track status. This designation underscores the drug candidate’s potential as a treatment for metastatic non-small cell lung cancer (NSCLC) patients with EGFR mutations who have progressed after treatment with third-generation EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy.
SHR-A2009, a HER-targeted ADC, has advanced into Phase II clinical trials. Additionally, a global, multi-center Phase I study for solid tumors has commenced across 16 countries, with China, Japan, and South Korea being among the first to participate. To date, no similar product has been approved for marketing worldwide, highlighting the novelty and potential impact of SHR-A2009 in the treatment landscape.- Flcube.com
